The <i>in Vitro</i> Characterisation of the Effect of Selexipag on Small Human Pulmonary Arteries

Objective: There is a lack of data on the direct effects Selexipag, novel prostacyclin Inositol phosphate-3 receptor (IP3) agonist with long half-life, human pulmonary arteries. This study aims to establish efficacy and potency Selexipag Methods: Patient consent was obtained prior lung resection for primary cancer. The artery rings (n = 23 from 6 patients) were cut 2 - 4 mm length internal diameter. They mounted wire myograph under physiological conditions pre-constricted prostaglandin F2α. Concentration response curves constructed by cumulative addition chambers. viability confirmed Acetylcholine potassium chloride. Results: caused dose dependent vasodilation range doses used 1 pM 30 uM, n excluded due non-reactivity 19 included. Initial significant PAs noted at 3 uM. Maximal achieved 10 uM (EC50 1.21 uM). Conclusion: demonstrated vasodilatory effect PAs. may be clinically effective in treatment arterial hypertension. However, additional are needed validate results this determine its clinical significance.